Expansion of Toxicologic Pathology Peer Review Through the Acquisition of ルナパス毒性病理研究所
First written in FY2022-Q3. 3 of 4 entries say "Restated". Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3RestatedAnnual report
「In addition, the pathology peer review business of 株式会社ルナパス毒性病理研究所, which became a consolidated subsidiary at the end of December 2021, continued to perform steadily.」
The Company reconfirmed that the pathology peer review business of 株式会社ルナパス毒性病理研究所 continued to perform steadily after it became a subsidiary. - FY2023-Q2RestatedAnnual report
「In addition, the pathology peer review business of 株式会社ルナパス毒性病理研究所, which became a consolidated subsidiary at the end of December 2021, continued to perform steadily.」
The Company reconfirmed that the pathology peer review business of 株式会社ルナパス毒性病理研究所 continued to perform steadily after it became a subsidiary. - FY2023-Q1RestatedAnnual report
「In addition, the pathology peer review business of 株式会社ルナパス毒性病理研究所, which became a consolidated subsidiary at the end of December 2021, continued to perform steadily.」
The Company reconfirmed that, following the acquisition of 株式会社ルナパス毒性病理研究所 as a subsidiary, its pathology peer review business for long-term toxicity and carcinogenicity studies and other areas continued to perform steadily. - FY2022-Q3First statedAnnual report
「In addition, the Company acquired all shares of 株式会社ルナパス毒性病理研究所, which provides pathology peer review services for long-term toxicity and carcinogenicity studies, areas where demand has increased in recent years, to major domestic pharmaceutical and CRO companies, and included the company in its scope of consolidation.」
株式会社ルナパス毒性病理研究所, which provides pathology peer review for long-term toxicity and carcinogenicity studies, became a subsidiary through the acquisition of all its shares, expanding the toxicologic pathology services area of the drug discovery support business.